Home > Neurology > AAN 2022 > Multiple Sclerosis > Evobrutinib reduces volume of slowly expanding lesions

Evobrutinib reduces volume of slowly expanding lesions

Presented By
Prof. Douglas Arnold, McGill University, Canada
Presented by
Douglas Arnold McGill University
Conference
AAN 2022
Doi
https://doi.org/10.55788/77e06c67
The highly selective Bruton’s tyrosine kinase (BTK) inhibitor evobrutinib reduced the volume of slowly expanding lesions (SEL) in a phase 2 trial. This effect was dose-dependent and especially apparent in more advanced multiple sclerosis (MS). This is the first evidence that a BTK inhibitor impacts brain lesions associated with chronic inflammation and tissue loss. Evobrutinib is a highly selective BTK inhibitor that targets B cells, macrophages, and microglia. In a phase 2 trial (NCT02975349) in patients with relapsing MS, 75 mg twice-daily evobrutinib reduced T1 gadolinium-enhancing lesions versus placebo during weeks 12 through 24 [1]. The current study focused on the effect of evobrutinib versus a comparator on an emerging MRI biomarker: SELs, also referred to as “smouldering lesions” [2]. SELs are chronically active, demyelinated MS lesions, l...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on